A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
University of Chicago
University of Chicago
M.D. Anderson Cancer Center
Emory University
Anhui Provincial Cancer Hospital
Semnan University of Medical Sciences
University of Cincinnati
Dana-Farber Cancer Institute
National Heart, Lung, and Blood Institute (NHLBI)
M.D. Anderson Cancer Center
Sir Mortimer B. Davis - Jewish General Hospital
Wake Forest University Health Sciences
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
University of Rochester
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of Illinois at Chicago
Repros Therapeutics Inc.
University of Arkansas
M.D. Anderson Cancer Center
PrECOG, LLC.
M.D. Anderson Cancer Center
University of Minnesota
Boston VA Research Institute, Inc.
University of Minnesota
Milton S. Hershey Medical Center
Accelerated Community Oncology Research Network
M.D. Anderson Cancer Center
British Columbia Cancer Agency
Ainos, Inc. (f/k/a Amarillo Biosciences Inc.
Dartmouth-Hitchcock Medical Center